Suppression of tumorigenicity 2 (ST2)

Included in meta analysis


Meijers WC, Van del Velde AR, Kobold ACM, et al, 2017, Eur J Hearth Failure , 19, 357-65 , Variability of biomarkers in patients with chronic heart failure and healthy controls


Total Score


Parameter Score
1. Scale A
2. Study Population A
3. Samples B
4. Measurand C
5. Pre-Analytical B
6. Replicate Analysis A
7. Steady State A
8. Outlier Analysis C
9. Normality A
10. Variance Homogeneity C
12. CI A
13. No of Results A
14. Concentrations A
15. Total Score C4,8,10

Item Details

Parameter Score
Matrix Plasma
Measurand Suppression of tumorigenicity 2 (ST2)
Unit ng / mL
Overall Analytical Principle Method Immunoassay; ELISA
Number of Subjects 28
Number of Subjects included in BV estimation 28
Ethinicity Unknown
Age Mean / Median 43.0
Age Min
Age Max
Age SD 13.0
Number of Males 14
Number of Females 14
State of Well Being
Healthy (excl pregnant)
Study Duration Length 4
Study Duration Units Week
Sampling Intervals, e.g. X sample(s) per Interval Unit 1
Interval Units Week
Sampling Times Start Time:
End Time:
Number of Samples 5
Average Number of Samples Used for BV Estimation 5.0
Average Number of Replicates
Estimates of CVi 10.5
Calculated Confidence Intervals of CVi Lower: 9.10, Upper: 12.19
Estimates of CVg 30.4
Calculated Confidence Intervals of CVg Lower: 23.94, Upper: 41.35
Analytical CV 2.9
Calculated Confidence Intervals of Analytical CV Lower: 2.12, Upper: 4.57
Measurand Mean 22.0
Measurand Min 19.6
Measurand Max 27.4
Measurand SD